Tech Enhanced Investing

Fabtech Technologies Cleanrooms is currently trading at RS 290.00 on the BSE, marking a gain of 7.50 points or 2.65% compared to its previous closing of RS 282.50.

The stock opened at RS 290.00 and touched an intraday high and low of RS 290.00 each. A total of 2,000 shares have been traded so far on the counter.

The BSE Group ‘M’ stock, with a face value of RS 10, had earlier recorded a 52-week high of RS 470.00 on July 21, 2025, and a 52-week low of RS 161.50 on January 10, 2026. Over the past week, the stock registered a high of RS 335.00 and a low of RS 301.95. The company’s current market capitalization stands at RS 357.26 crore.

In terms of shareholding pattern, promoters hold 68.49% stake in the company, while institutional investors and non-institutional investors hold 8.97% and 22.54% respectively.

In a key development, the company’s Board of Directors has approved the acquisition of 38,673 equity shares in Advantek Air Systems. The decision was taken at the board meeting held on February 12, 2026. The acquisition, aligned with the company’s core business operations, is aimed at supporting business expansion.

The transaction will be completed for a total cash consideration of RS 2.54 crore.

Fabtech Technologies Cleanrooms operates in the manufacturing of pre-engineered and pre-fabricated modular panels and doors used for developing internal infrastructure for pharmaceutical and allied industries.

Shares of Alkem Laboratories were trading at RS 5460.05, up by 58.50 points or 1.08% from the previous closing of RS 5401.55 on the BSE.

The stock opened at RS 5429.20 and touched an intraday high of RS 5538.35 and a low of RS 5384.50. A total of 1,894 shares were traded on the counter so far.

The BSE Group ‘A’ stock with a face value of RS 2 hit its 52-week high of RS 5933.00 on January 13, 2026, and a 52-week low of RS 4498.90 on February 28, 2025. Over the past week, the stock recorded a high of RS 5910.00 and a low of RS 5332.45. The company’s current market capitalization stands at RS 65677.05 crore.

In terms of shareholding, promoters hold 51.20% stake in the company, while Institutions and Non-Institutions account for 31.51% and 17.30%, respectively.

On the financial front, Alkem Laboratories reported a 13.96% decline in its standalone net profit at RS 622.14 crore for the third quarter ended December 31, 2025, compared to RS 723.12 crore in the same quarter of the previous year. However, the company’s total income rose 6.79% to RS 2622.80 crore in Q3FY26, up from RS 2456.01 crore in the corresponding quarter last year.

On a consolidated basis, the company posted a marginal increase in net profit to RS 636.02 crore for the quarter ended December 31, 2025, as against RS 625.82 crore in the year-ago period. Consolidated total income grew 11.90% to RS 3879.92 crore in Q3FY26, compared to RS 3467.27 crore in the corresponding quarter of the previous year.

Techknowgreen Solutions is currently trading at RS 113.00, up by 2.00 points or 1.80% from its previous closing of RS 111.00 on the BSE.

The stock opened at RS 106.20 and touched an intraday high of RS 113.00 and a low of RS 106.20. So far, 3,600 shares have been traded on the counter.

The BSE Group ‘M’ stock with a face value of RS 10 reached its 52-week high of RS 207.00 on February 14, 2025, and a 52-week low of RS 98.00 on February 02, 2026. During the past week, the stock recorded a high of RS 120.70 and a low of RS 105.00. The company’s current market capitalization stands at RS 83.42 crore.

Promoters hold a 65.58% stake in the company, while non-institutional investors account for 34.42% shareholding.

In a significant development, Techknowgreen Solutions has secured a work order worth $190,598.00 (including tax) from Sterling & Wilson Data Center, Riyadh, Kingdom of Saudi Arabia. The contract involves comprehensive Environmental Project Criteria evaluation and implementation for the ‘RUH-East Data Center’ project in Riyadh. The project is scheduled to be completed within 18 months.

Techknowgreen Solutions operates in the field of environmental and infrastructure planning consultancy, offering sustainable and economically viable solutions to environmental and climate change challenges.

Zydus Lifesciences shares were trading at RS 910.65, rising by 5.80 points or 0.64% from the previous close of RS 904.85 on the BSE. The stock opened at RS 904.80 and touched an intraday high of RS 916.00 and a low of RS 904.25. A total of 3,360 shares changed hands on the counter.

The BSE Group ‘A’ stock with a face value of RS 1 hit a 52-week high of RS 1059.00 on 19-Sep-2025 and a 52-week low of RS 797.05 on 07-Apr-2025. Over the past week, the scrip recorded a high of RS 933.40 and a low of RS 882.00. The company’s current market capitalisation stands at RS 91788.66 crore.

Promoters hold a 75.00% stake in the company, while institutional and non-institutional investors own 18.15% and 6.85%, respectively.

In a key development, the company has received final approval from the United States Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12% (USRLD: Lac-Hydrin Cream, 12%).

Ammonium lactate cream, 12% is a topical prescription medicine indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris, a hereditary skin condition. The formulation works by enhancing skin hydration and, as an alpha-hydroxy acid, helps reduce itching, soften the skin, and minimise scaling.

The product will be manufactured at the group’s topical manufacturing facility in Changodar, Ahmedabad, and marketed in the US by Viona Pharmaceuticals Inc.. According to IQVIA MAT December 2025 data, the product recorded annual sales of $15 million in the United States.

With this approval, the group now has 430 approvals and has filed 505 ANDAs since initiating the filing process in FY 2003-04.

Zydus Lifesciences, formerly known as Cadila Healthcare, is an integrated pharmaceutical company engaged across the entire value chain, including research, development, manufacturing, marketing, and distribution of pharmaceutical products.

Natco Pharma shares surged sharply on the BSE, currently trading at RS 885.35, up by 63.25 points or 7.69% compared to its previous close of RS 822.10.

The stock opened at RS 825.05 and touched an intraday high of RS 895.00 and a low of RS 825.05. A total of 382 shares have been traded so far on the counter.

The BSE Group ‘A’ stock with a face value of RS 2 had earlier touched a 52-week high of RS 1059.60 on July 24, 2025, and a 52-week low of RS 660.05 on April 7, 2025. Over the past week, the scrip recorded a high of RS 895.00 and a low of RS 815.05. The company’s current market capitalization stands at RS 14724.62 crore.

In terms of shareholding pattern, promoters hold 49.48% stake in the company, while Institutional investors and Non-Institutional investors hold 20.54% and 29.97% respectively.

The rally comes after the company received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market a generic version of Semaglutide Injection in India. The company plans to launch the product in March 2026. Semaglutide is prescribed for adults with inadequately controlled type 2 diabetes mellitus and is used alongside diet and exercise.

Natco Pharma was originally incorporated as a private company and operates in the research, development, manufacturing, and marketing of pharmaceutical substances and finished dosage formulations for both domestic and international markets.

Hexaware Technologies surged 5.54% to trade at RS 574.10, rising by 30.15 points from its previous closing of RS 543.95 on the Bombay Stock Exchange (BSE).

The stock opened at RS 526.80 and touched an intraday high of RS 580.40 and a low of RS 521.25. A total of 73,280 shares were traded on the counter during the session.

The BSE Group ‘A’ stock with a face value of RS 1 had earlier hit a 52-week high of RS 900.15 on July 9, 2025, and a 52-week low of RS 521.25 on February 13, 2026. Over the past week, the stock recorded a high of RS 622.15 and a low of RS 521.25. The company’s current market capitalization stands at RS 33,193.44 crore.

In terms of shareholding pattern, promoters hold a 74.30% stake in the company, while institutional investors and non-institutional investors account for 19.46% and 6.23%, respectively.

Hexaware Technologies has announced a strategic partnership with CareInsight, combining AI-native healthcare platforms with advanced AI and digital transformation expertise. The collaboration aims to deliver outcome-driven, production-grade AI solutions at scale for healthcare organizations, focusing on measurable improvements in operations, decision-making, and patient care delivery.

The partnership is structured to enable healthcare organizations to deploy AI in real-world settings by facilitating integrated data flows, operational intelligence, and outcome-focused applications across the healthcare continuum. By leveraging CareInsight’s AI platforms alongside Hexaware’s implementation and transformation capabilities, the alliance seeks to reduce administrative complexities, enhance operational coordination, and support faster, data-driven decision-making.

Through this collaboration, both companies aim to help healthcare providers transform AI into a practical, everyday advantage—driving smarter decisions, streamlined operations, and improved patient experiences at scale.

Hexaware Technologies is a global digital and technology services company with artificial intelligence at its core, serving a diverse client base across the Americas, Europe, and the Asia-Pacific region, including India and the Middle East.

Hindustan Aeronautics Limited shares were trading at RS 4184.45, gaining 25.80 points or 0.62% from the previous close of RS 4158.65 on the Bombay Stock Exchange (BSE).

The stock opened at RS 4199.80 and moved between an intraday high of RS 4222.35 and a low of RS 4156.05. A total of 58,224 shares were traded on the counter during the session so far.

The BSE Group ‘A’ stock, with a face value of RS 5, had touched a 52-week high of RS 5166.00 on May 16, 2025, and a 52-week low of RS 3045.95 on March 3, 2025. Over the past week, the stock recorded a high of RS 4222.35 and a low of RS 4015.00. The company’s current market capitalization stands at RS 279551.29 crore.

In terms of shareholding pattern, promoters hold 71.64% stake in the company, while institutional investors and non-institutional investors account for 20.60% and 7.76%, respectively.

For the third quarter ended December 31, 2025, the company reported a 29.26% increase in standalone net profit at RS 1,851.72 crore, compared to RS 1,432.60 crore in the corresponding quarter of the previous year. Total income rose 13.50% to RS 8,612.38 crore in Q3FY26, as against RS 7,588.08 crore in the same period last year.

On a consolidated basis, net profit surged 29.65% to RS 1,866.68 crore for the quarter ended December 31, 2025, compared to RS 1,439.83 crore in the year-ago period. Consolidated total income increased 13.49% to RS 8,612.60 crore in Q3FY26, up from RS 7,588.71 crore in the corresponding quarter of the previous fiscal.

Bajaj Finance is currently trading at RS 1005.55, up by 5.75 points or 0.58% from its previous closing of RS 999.80 on the BSE.

The stock opened at RS 999.80 and touched an intraday high of RS 1008.25 and a low of RS 993.40. A total of 1,94,334 shares have been traded on the counter so far.

The BSE Group ‘A’ stock, with a face value of RS 1, recorded a 52-week high of RS 1102.45 on October 23, 2025, and a 52-week low of RS 810.21 on April 7, 2025. Over the past week, the stock’s high and low stood at RS 1008.25 and RS 961.45, respectively. The company’s current market capitalization stands at RS 624519.39 crore.

In terms of shareholding, promoters hold 54.70% stake in the company, while Institutions and Non-Institutions account for 36.44% and 8.86%, respectively.

In a key development, Bajaj Finance has raised RS 500 crore through the allotment of 50,000 Secured Redeemable Non-Convertible Debentures (NCDs) at a face value of RS 1 lakh each on a private placement basis. The NCDs carry an annual coupon rate of 7.31% per annum and are proposed to be listed on the Wholesale Debt Market Segment of the BSE. The Debenture Allotment Committee approved the allotment at its meeting held on February 12, 2026.

Bajaj Finance is among the leading players in India’s rapidly expanding consumer finance segment and is recognized as a pioneer in offering interest-free EMI financing options across categories such as consumer durables, lifestyle products, and groceries.

Goldiam International is trading higher at RS 390.80, registering a gain of 7.10 points or 1.85% compared to its previous close of RS 383.70 on the BSE.

The stock opened at RS 378.00 and touched an intraday high of RS 392.25 and a low of RS 377.95. A total of 18,719 shares have been traded on the counter so far.

The BSE Group ‘A’ stock, with a face value of RS 2, had earlier hit a 52-week high of RS 444.35 on February 10, 2026, and a 52-week low of RS 252.00 on April 7, 2025. Over the past week, the stock recorded a high of RS 444.35 and a low of RS 377.95.

The company’s current market capitalization stands at RS 4,359.76 crore. Promoters hold a 58.51% stake in the company, while institutional and non-institutional investors account for 1.84% and 39.65%, respectively.

In a business update, Goldiam International has launched a new retail store under its brand name ‘ORIGEM’ on February 12, 2026, at Phoenix Marketcity Mall in Velachery, Chennai. With this addition, the company’s total store count has increased to 15.

Earlier this month, on February 3, 2026, the company inaugurated its 14th retail outlet at South City Mall in Kolkata.

Goldiam International is engaged in the manufacturing and export of jewellery, offering a wide range of designs across rings, earrings, pendants, and other categories.

Shilpa Medicare is currently trading at RS 329.00, rising by 5.70 points or 1.76% from its previous closing of RS 323.30 on the Bombay Stock Exchange (BSE).

The stock opened at RS 321.00 and touched an intraday high of RS 332.00 and a low of RS 315.60. A total of 6,330 shares have been traded so far.

The BSE Group ‘A’ stock with a face value of RS 1 hit a 52-week high of RS 501.60 on June 16, 2025, and a 52-week low of RS 260.00 on January 27, 2026. Over the past week, the stock recorded a high of RS 359.95 and a low of RS 315.60. The company’s current market capitalization stands at RS 6,394.55 crore.

Promoters hold a 40.13% stake in the company, while institutional and non-institutional investors hold 19.30% and 40.56%, respectively.

In a key development, Shilpa Medicare has entered into a long-term strategic development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland, for a novel therapy targeting autoimmune and alloimmune disorders. Under the agreement, the Shilpa group will provide comprehensive CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support. The collaboration spans early-stage development through commercialization, positioning Shilpa as a lifecycle partner for the program.

The autoimmune and immune-modulation segment is among the fastest-growing therapeutic categories globally, driven by rising disease prevalence and increasing demand for targeted immunotherapies. By securing this mandate at an early stage, Shilpa strengthens its presence in high-value, innovation-driven pipelines with scalable commercial potential.

This marks the third major international development and manufacturing contract secured by the company, highlighting growing demand from Western biotech firms for its integrated R&D capabilities and advanced GMP manufacturing infrastructure. While financial details remain undisclosed, the agreement includes milestone-linked expansion opportunities and may evolve into a multi-year commercial supply arrangement, subject to successful clinical and regulatory progress.

Shilpa Medicare manufactures and exports high-quality Active Pharmaceutical Ingredients (APIs), fine chemicals, intermediates, herbal products, and specialty chemical products using advanced technology and adhering strictly to international quality standards.